{"id":"NCT00658528","sponsor":"Eisai Inc.","briefTitle":"Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)","officialTitle":"A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-02","primaryCompletion":"2009-09","completion":"2010-01","firstPosted":"2008-04-15","resultsPosted":"2015-06-23","lastUpdate":"2015-12-21"},"enrollment":1061,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Gastroesophageal Reflux Disease (GERD)"],"interventions":[{"type":"DRUG","name":"Rabeprazole sodium","otherNames":["Aciphex"]},{"type":"DRUG","name":"Esomeprazole","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to determine the safety and efficacy of Rabeprazole extended release (ER) 50 mg versus Esomeprazole 40 mg for healing and symptomatic relief among subjects with erosive gastroesophageal reflux disease (GERD).","primaryOutcome":{"measure":"Percentage of Participants With Erosive Gastroesophageal Reflux Disease (eGERD) Who Achieved Endoscopically-confirmed Healing by 8 Weeks","timeFrame":"Baseline and Week 8","effectByArm":[{"arm":"ESO 40 mg","deltaMin":75,"sd":null},{"arm":"RAB ER 50 mg","deltaMin":80,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":88,"countries":["United States","Argentina","Australia","Bulgaria","Canada","Chile","Croatia","Estonia","France","Germany","Hungary","India","Latvia"]},"refs":{"pmids":["21114792"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":528},"commonTop":[]}}